Literature DB >> 22293228

Sex-specific associations of serum prolactin concentrations with cardiac remodeling: longitudinal results from the Study of Health Pomerania (SHIP).

Robin Haring1, Henry Völzke, Ramachandran S Vasan, Stephan B Felix, Matthias Nauck, Marcus Dörr, Henri Wallaschofski.   

Abstract

BACKGROUND: Previous experimental and patient-based studies suggest that prolactin (PRL) and its 16 kDa fragment influence cardiovascular phenotypes by modulating angiogenesis. The association between serum PRL and cardiac remodeling in the general population is unknown.
METHODS: We evaluated 804 individuals (441 women) from the population-based Study of Health in Pomerania, aged ≥ 45 years, with available baseline serum PRL who underwent serial echocardiography at baseline and five-year follow-up. Left ventricular mass (LVM) was calculated and left ventricular hypertrophy (LVH) defined by sex-specific distributions of LVM. LV geometry was defined on the basis of relative wall thickness (RWT) and LVH. Sex-specific multivariable regression analyses were performed relating PRL (independent variable modelled as a continuous variable and as sex-specific quartiles) to change in LVM, RWT, and to incident LVH and abnormal geometry.
RESULTS: Baseline PRL concentrations were inversely associated with LVM change in men, but not in women (β per 10% decrease in PRL: 0.37; 95% CI, 0.13-0.60 in men and -0.02; 95% CI, -0.21 to 0.17 in women, respectively). In men, baseline PRL concentrations were also inversely associated with incident LVH [first vs. fourth PRL quartile: relative risk (RR) 2.26 (95% CI, 1.20-4.24)] and altered LV geometry on follow-up [RR for incident concentric hypertrophy per 10% decrease in PRL: 1.20 (95% CI, 1.06-1.37)]. None of the longitudinal associations were observed in women.
CONCLUSION: We observed inverse associations of PRL with LVM change, incident LVH, and altered LV geometry in men, but not in women. Additional studies are warranted to confirm our findings and to elucidate the mechanisms underlying these sex-specific associations.
Copyright © 2012 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22293228     DOI: 10.1016/j.atherosclerosis.2012.01.017

Source DB:  PubMed          Journal:  Atherosclerosis        ISSN: 0021-9150            Impact factor:   5.162


  7 in total

1.  Prolactin as a predictor of endothelial dysfunction and arterial stiffness progression in menopause.

Authors:  G Georgiopoulos; I Lambrinoudaki; F Athanasouli; E Armeni; A Koliviras; A Augoulea; D Rizos; C Papamichael; A Protogerou; K Stellos; K Stamatelopoulos
Journal:  J Hum Hypertens       Date:  2017-03-23       Impact factor: 3.012

Review 2.  The role of prolactin in andrology: what is new?

Authors:  Giulia Rastrelli; Giovanni Corona; Mario Maggi
Journal:  Rev Endocr Metab Disord       Date:  2015-09       Impact factor: 6.514

3.  Serum Prolactin and Cardiac Remodeling in Subjects with Prediabetes.

Authors:  Jin Hwa Kim
Journal:  Diabetes Metab J       Date:  2017-06       Impact factor: 5.376

4.  Impact of Gender on the Association between Low Serum Prolactin and Left Ventricular Mass in Subjects with Prediabetes.

Authors:  Mervat M El-Eshmawy; Enas M Elkhamisy; Eman Elsayed; Shaheer Kamal
Journal:  Diabetes Metab J       Date:  2017-06       Impact factor: 5.376

5.  Association between serum prolactin levels and insulin resistance in non-diabetic men.

Authors:  Makoto Daimon; Aya Kamba; Hiroshi Murakami; Satoru Mizushiri; Sho Osonoi; Masato Yamaichi; Kota Matsuki; Eri Sato; Jutaro Tanabe; Shinobu Takayasu; Yuki Matsuhashi; Miyuki Yanagimachi; Ken Terui; Kazunori Kageyama; Itoyo Tokuda; Ippei Takahashi; Shigeyuki Nakaji
Journal:  PLoS One       Date:  2017-04-06       Impact factor: 3.240

6.  Serum prolactin concentrations as risk factor of metabolic syndrome or type 2 diabetes?

Authors:  Lisa Balbach; Henri Wallaschofski; Henry Völzke; Matthias Nauck; Marcus Dörr; Robin Haring
Journal:  BMC Endocr Disord       Date:  2013-03-21       Impact factor: 2.763

7.  Circulating adiponectin and cardiovascular mortality in patients with type 2 diabetes mellitus: evidence of sexual dimorphism.

Authors:  Claudia Menzaghi; Min Xu; Lucia Salvemini; Concetta De Bonis; Giuseppe Palladino; Tao Huang; Massimiliano Copetti; Yan Zheng; Yanping Li; Grazia Fini; Frank B Hu; Simonetta Bacci; Lu Qi; Vincenzo Trischitta
Journal:  Cardiovasc Diabetol       Date:  2014-09-10       Impact factor: 9.951

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.